These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22677416)

  • 1. Preparation of medicines for children - a hierarchy of classification.
    Ernest TB; Craig J; Nunn A; Salunke S; Tuleu C; Breitkreutz J; Alex R; Hempenstall J
    Int J Pharm; 2012 Oct; 435(2):124-30. PubMed ID: 22677416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing paediatric medicines: identifying the needs and recognizing the challenges.
    Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
    J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WHO Expert Committee on specifications for pharmaceutical preparations.
    World Health Organ Tech Rep Ser; 1996; 863():1-194. PubMed ID: 8952445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development, validation and transfer of a near infrared method to determine in-line the end point of a fluidised drying process for commercial production batches of an approved oral solid dose pharmaceutical product.
    Peinado A; Hammond J; Scott A
    J Pharm Biomed Anal; 2011 Jan; 54(1):13-20. PubMed ID: 20801599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poor preservation efficacy versus quality and safety of pediatric extemporaneous liquids.
    Ghulam A; Keen K; Tuleu C; Wong IC; Long PF
    Ann Pharmacother; 2007 May; 41(5):857-60. PubMed ID: 17440007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How do Japanese children take their medicines, and what are pharmacists and paediatricians doing about it?
    Nakamura H; Ishikawa Y
    Int J Pharm; 2014 Aug; 469(2):249-50. PubMed ID: 24704105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of acceptability of oral paediatric medicines: a review.
    Mistry P; Batchelor H;
    J Pharm Pharmacol; 2017 Apr; 69(4):361-376. PubMed ID: 27524471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extemporaneous compounding in a sample of New Zealand hospitals: a retrospective survey.
    Kairuz T; Chhim S; Hasan F; Kumar K; Lal A; Patel R; Singh R; Dogra M; Garg S
    N Z Med J; 2007 Mar; 120(1251):U2466. PubMed ID: 17384694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to age-appropriate essential medicines: a retrospective survey of compounding of medicines for children in hospitals in Nigeria and implications for policy development.
    Orubu ES; Okwelogu C; Opanuga O; Nunn T; Tuleu C
    Health Policy Plan; 2017 Mar; 32(2):225-235. PubMed ID: 28207051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing United States Pharmacopeia Chapter <1163>. Quality assurance in pharmaceutical compounding, Part 3: Testing.
    Allen LV
    Int J Pharm Compd; 2012; 16(4):322-8. PubMed ID: 23050393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of sterile product compounding practices in Canadian hospital pharmacies.
    Fitch DP; Hall KW
    Can J Hosp Pharm; 1993 Dec; 46(6):249-60. PubMed ID: 10131343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosage form design and development.
    Allen LV
    Clin Ther; 2008 Nov; 30(11):2102-11. PubMed ID: 19108798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compounded medicines and 'off label' prescribing - a case for more guidance.
    Fois RA; Mewes BT; McLachlan AJ; Ramzan I
    Aust Fam Physician; 2009; 38(1-2):16-20. PubMed ID: 19283230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality, safety and efficacy in the 'off-label' use of medicines.
    Kairuz TE; Gargiulo D; Bunt C; Garg S
    Curr Drug Saf; 2007 Jan; 2(1):89-95. PubMed ID: 18690954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in availability of paediatric medicines in Australia between 1998 and 2002.
    Chui J; Tordoff J; Reith D
    Br J Clin Pharmacol; 2005 Jun; 59(6):736-42. PubMed ID: 15948941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and Administration of Biological Medicinal Products".
    Krämer I; Thiesen J; Astier A
    Pharm Res; 2020 Aug; 37(8):159. PubMed ID: 32743712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drugs for children--when temporary solutions become routine].
    Kalikstad B; Westergren T
    Tidsskr Nor Laegeforen; 2006 Mar; 126(7):930-2. PubMed ID: 16554887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.